Iroquois Capital Management LLC 13D and 13G filings for Biodexa Pharmaceuticals Plc:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-14 5:12 pm Sale |
2024-09-30 | 13G | Biodexa Pharmaceuticals Plc BDRX |
Iroquois Capital Management LLC | 112,077 0.670% |
-44,718,963 (-99.75%) |
Filing |
| 2024-08-08 4:24 pm Purchase |
2024-07-19 | 13G | Biodexa Pharmaceuticals Plc BDRX |
Iroquois Capital Management LLC | 44,831,040 9.990% |
44,831,040 (New Position) |
Filing |
| 2024-08-05 09:00 am Purchase |
2024-07-19 | 13G | Biodexa Pharmaceuticals Plc BDRX |
Iroquois Capital Management LLC | 44,831,040 9.990% |
44,831,040 (New Position) |
Filing |